Your browser doesn't support javascript.
Outcomes among Hospitalized Chronic Kidney Disease Patients with COVID-19.
Khatri, Minesh; Charytan, David M; Parnia, Sam; Petrilli, Christopher M; Michael, Jeffrey; Liu, David; Tatapudi, Vasishta; Jones, Simon; Benstein, Judith; Horwitz, Leora I.
  • Khatri M; New York University Long Island School of Medicine, Mineola, New York.
  • Charytan DM; Department of Medicine, New York University Grossman School of Medicine, New York, New York.
  • Parnia S; Department of Medicine, New York University Grossman School of Medicine, New York, New York.
  • Petrilli CM; Department of Medicine, New York University Grossman School of Medicine, New York, New York.
  • Michael J; Department of Medicine, New York University Grossman School of Medicine, New York, New York.
  • Liu D; Department of Medicine, New York University Grossman School of Medicine, New York, New York.
  • Tatapudi V; Department of Medicine, New York University Grossman School of Medicine, New York, New York.
  • Jones S; Department of Population Health, New York University Grossman School of Medicine, New York, New York.
  • Benstein J; Department of Medicine, New York University Grossman School of Medicine, New York, New York.
  • Horwitz LI; Department of Medicine, New York University Grossman School of Medicine, New York, New York.
Kidney360 ; 2(7): 1107-1114, 2021 07 29.
Article in English | MEDLINE | ID: covidwho-1776887
ABSTRACT

Background:

Patients with CKD ha ve impaired immunity, increased risk of infection-related mortality, and worsened COVID-19 outcomes. However, data comparing nondialysis CKD and ESKD are sparse.

Methods:

Patients with COVID-19 admitted to three hospitals in the New York area, between March 2 and August 27, 2020, were retrospectively studied using electronic health records. Patients were classified as those without CKD, those with nondialysis CKD, and those with ESKD, with outcomes including hospital mortality, ICU admission, and mortality rates.

Results:

Of 3905 patients, 588 (15%) had nondialysis CKD and 128 (3%) had ESKD. The nondialysis CKD and ESKD groups had a greater prevalence of comorbidities and higher admission D-dimer levels, whereas patients with ESKD had lower C-reactive protein levels at admission. ICU admission rates were similar across all three groups (23%-25%). The overall, unadjusted hospital mortality was 25%, and the mortality was 24% for those without CKD, 34% for those with nondialysis CKD, and 27% for those with ESKD. Among patients in the ICU, mortality was 56%, 64%, and 56%, respectively. Although patients with nondialysis CKD had higher odds of overall mortality versus those without CKD in univariate analysis (OR, 1.58; 95% CI, 1.31 to 1.91), this was no longer significant in fully adjusted models (OR, 1.11; 95% CI, 0.88 to 1.40). Also, ESKD status did not associate with a higher risk of mortality compared with non-CKD in adjusted analyses, but did have reduced mortality when compared with nondialysis CKD (OR, 0.57; 95% CI, 0.33 to 0.95). Mortality rates declined precipitously after the first 2 months of the pandemic, from 26% to 14%, which was reflected in all three subgroups.

Conclusions:

In a diverse cohort of patients with COVID-19, we observed higher crude mortality rates for patients with nondialysis CKD and, to a lesser extent, ESKD, which were not significant after risk adjustment. Moreover, patients with ESKD appear to have better outcom es than those with nondialysis CKD.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Renal Insufficiency, Chronic / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Kidney360 Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Renal Insufficiency, Chronic / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Kidney360 Year: 2021 Document Type: Article